Table 2.
Distributions of Selected Demographic, Clinical, and Molecular Characteristics by DNA Methylation Cluster (p<0.10)
| Cluster 1 (N=134) | Cluster 2 (N=137) | P value | |
|---|---|---|---|
|
| |||
| Illumina Infinium Methylation BeadChip | 0.042 | ||
| MethylationEPIC | 120 (90%) | 110 (80%) | |
| HumanMethylation450k | 14 (10%) | 27 (20%) | |
| Self-reported race | 0.012 | ||
| White non-Hispanic | 95 (92%) | 85 (80%) | |
| Asian | 6 (6%) | 19 (18%) | |
| Black | 2 (2%) | 2 (2%) | |
| Missing/other | 31 | 31 | |
| FIGO stage | 0.022 | ||
| Early (I, II) | 73 (57%) | 93 (72%) | |
| Advanced (III, IV) | 54 (42%) | 37 (28%) | |
| Unknown | 7 | 7 | |
| Residual disease | 0.065 | ||
| No macroscopic | 85 (71%) | 96 (81%) | |
| Macroscopic | 35 (29%) | 22 (19%) | |
| Unknown | 14 | 19 | |
| p53 expression | 0.013 | ||
| Wild type pattern: variable intensity 1–90% of nuclei | 13 (72%) | 22 (100%) | |
| Complete absence with internal control | 2 (11%) | 0 | |
| Overexpression, strong intensity >90% of nuclei | 3 (17%) | 0 | |
| Unknown | 116 | 115 | |
| TP53 mutation | <0.001 | ||
| Yes | 37 (31%) | 10 (9%) | |
| No | 82 (69%) | 105 (91%) | |
| Unknown | 15 | 22 | |
| ARID1A mutation | <0.001 | ||
| Yes | 38 (32%) | 73 (63%) | |
| No | 81 (68%) | 42 (37%) | |
| Unknown | 15 | 22 | |
| PIK3CA mutation | 0.002 | ||
| Yes | 39 (33%) | 62 (54%) | |
| No | 80 (67%) | 53 (46%) | |
| Unknown | 15 | 22 | |
| ARID1A/PIK3CA mutation | <0.001 | ||
| Yes/yes | 18 (15%) | 48 (42%) | |
| Yes/no | 20 (17%) | 25 (22%) | |
| No/yes | 21 (18%) | 14 (12%) | |
| No/no | 60 (50%) | 28 (24%) | |
| Unknown | 15 | 22 | |
| Total aneuploidy | <0.001 | ||
| Mean (range) | 7.1 (0–27) | 11.1 (0–28) | |
| Unknown | 15 | 22 | |
| Somatic mutation group | <0.001 | ||
| ARID1A mutation with one other mutation in PIK3CA, PIK3R1, KRAS, PPP2R1A, SPOP, or TERT (Group A) | 21 (18%) | 24 (21%) | |
| Multiple ARID1A mutations with one other mutation in in PIK3CA or PIK3R (Group B) | 7 (6%) | 33 (28%) | |
| Single ARID1A mutation (Group C) | 8 (7%) | 3 (3%) | |
| Multiple ARID1A mutations without mutations in PIK3CA or PIK3R1 (Group D) | 2 (2%) | 13 (11%) | |
| Mutation in PIK3CA, PIK3R1, KRAS, PPP2R1A, SPOP, or TERT (Group E) | 29 (24%) | 27 (23%) | |
| TP53 mutation without mutations in ARID1A or SMARCA4 (Group F) | 28 (24%) | 4 (4%) | |
| SMARCA4 mutation (Group G) | 6 (5%) | 2 (2%) | |
| Undefined (Group H) | 18 (15%) | 9 (8%) | |
| Unknown | 15 | 22 | |
| Vital status | 0.01 | ||
| Alive | 69 (55%) | 90 (70%) | |
| Deceased | 56 (45%) | 38 (30%) | |
| Unknown | 9 | 9 | |
| Median survival, months | 58.7 | NA | 0.01 |
| Time to progression among progressors, months; mean (range), N | 16.6 (0.03–50.3), 68 | 20.9 (0.16–59.7), 69 | 0.07 |
Kruskal-Wallis sum test was used for categorical tests, unless any cell less than five, then Pearson’s chi-squared test with simulated p-value based on 2000 replicates used; Fisher’s exact test used for quantitative measures; FIGO, International Federation of Gynecology and Obstetrics; total aneuploidy: number of chromosomal or chromosomal arm level events.